FierceBiotech 2026年4月22日 AACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’
FierceBiotech 2026年4月22日 Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
FierceBiotech 2026年4月22日 Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
FierceBiotech 2026年4月22日 AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
FierceBiotech 2026年4月22日 Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
FierceBiotech 2026年4月22日 Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials
FierceBiotech 2026年4月21日 Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
FierceBiotech 2026年4月21日 In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
FierceBiotech 2026年4月21日 Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
FierceBiotech 2026年4月21日 Tortugas comes out of its shell with $106M to fund 4 phase 2-stage neuro drugs licensed from Asia
FierceBiotech 2026年4月21日 Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
FierceBiotech 2026年4月21日 Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure
FierceBiotech 2026年4月21日 With $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines
FierceBiotech 2026年4月21日 Replimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection
FierceBiotech 2026年4月20日 AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent